Engineered Mycobacteriophage TM4:: GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiae438 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Saranathan Rajagopalan und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Mycobacteriophages, Antitubercular Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Drug-resistant tuberculosis is a growing public health threat, and early characterization of the resistance phenotype is essential for guiding treatment and mitigating the high mortality associated with the disease. However, the slow growth rate of Mycobacterium tuberculosis, the causative agent of tuberculosis, necessitates several weeks for conventional culture-dependent drug susceptibility testing (DST). In addition, there are no widely available molecular diagnostic assays for evaluating resistance to newer tuberculosis drugs or drugs with complex resistance mechanisms.
Methods
We have developed a luciferase-based reporter mycobacteriophage assay that can determine drug resistance within 48 hours. We engineered the TM4 mycobacteriophage to express green enhanced nanoluciferase (GeNL) cassette and optimized DST for bedaquiline, pretomanid, linezolid, clofazimine, and rifampicin using clinical M. tuberculosis isolates.
Results
To assess the feasibility of this assay, we conducted a proof-of-principle study using 53 clinical M. tuberculosis isolates. TM4::GeNL phage DST effectively distinguished between sensitive and resistant isolates for bedaquiline and rifampicin at a concentration of 0.125 μg/mL. Optimal differentiation between sensitive and resistant isolates for pretomanid, clofazimine, and linezolid was achieved at concentrations of 0.5 μg/mL, 0.25 μg/mL, and 1 μg/mL, respectively. Additionally, TM4::GeNL DST identified low-level rifampicin resistance in clinical isolates even though they were classified as sensitive by Mycobacteria Growth Indicator Tube DST.
Conclusions
TM4::GeNL reporter phage DST offers a rapid method to identify M. tuberculosis drug resistance, including resistance to newer tuberculosis drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
- Wadsworth Center, New York State Department of Health, Albany, New York, USA.
- South African Medical Research Council-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
- Africa Health Research Institute, University of KwaZulu-Natal, Durban, South Africa.
- Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Pulmonology and Critical Care, University of KwaZulu-Natal, Durban, South Africa.
ORCID-Profile: William R Jacobs
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
Zitieren
APA
Rajagopalan, S., Rourke, A. K., Asare, E., Kohlerschmidt, D. J., Das, L., Ngema, S. L., Mulholland, C. V., Vilchèze, C., Mahalingam, V., Moodley, S., Truebody, B., Mackenzie, J., Steyn, A. J. C., Perumal, R., Berney, M., Larsen, M. H., O'Donnell, M. R., Escuyer, V. E., & Jacobs, W. R. (2025). Engineered Mycobacteriophage TM4:: GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae438
Vancouver
Rajagopalan S, Rourke AK, Asare E, Kohlerschmidt DJ, Das L, Ngema SL, et al. Engineered Mycobacteriophage TM4:: GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae438
BibTeX
@article{Rajagopalan2025,
author = {Rajagopalan, Saranathan and Rourke, Amy K and Asare, Emmanuel and Kohlerschmidt, Donna J and Das, Lahari and Ngema, Senamile L and Mulholland, Claire V and Vilchèze, Catherine and Mahalingam, Vaishnavi and Moodley, Sashen and Truebody, Barry and Mackenzie, Jared and Steyn, Adrie J C and Perumal, Rubeshan and Berney, Michael and Larsen, Michelle H and O'Donnell, Max R and Escuyer, Vincent E and Jacobs, William R},
title = {Engineered Mycobacteriophage TM4:: GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiae438}
}
EUVIMED